Role of Functional Polymorphisms of P53 and P73 Genes with the Risk of Prostate Cancer in a Case-Control Study from Northern India

Archives of Medical Research

Volumn 42, Issue 2, 2011, Pages 122-127

  Mittal, Rama Devi ^a   George, Ginu P ^a   Mishra, Jyotsna ^a   Mittal, Tulika ^a   Kapoor, Rakesh ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Haplotype; PCR CTPP; PCR RFLP; Polymorphism; Prostate cancer; Susceptibility

Indexed keywords

GENOMIC DNA; PROTEIN P73;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EXON; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; INDIA; INTRON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AGED; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INDIA; MALE; MIDDLE AGED; NUCLEAR PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79955746694     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.03.001     Document Type: Article

References (27)

1. Hughes C., Murphy A., Martin C., et al. Molecular pathology of prostate cancer. J Clin Pathol 2005, 58:673-684.
2. Schabath M.B., Wu X., Wei Q., et al. Combined effects of the P53 and 73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15:158-161.
3. Meyers F.J., Gumerlock P.H., Chi S.G., et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998, 83:2534-2539.
4. Huang S.P., Wu W.J., Chang W.S., et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:2217-2224.
5. Bonafe M., Ceccarelli C., Farabegoli F., et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003, 9:4860-4864.
6. Wu X., Zhao H., Amos C.I., et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002, 94:681-690.
7. Gleason D.F., Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974, 111:58-64.
8. Gangwar R., Mandhani A., Mittal R.D. Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in North Indian population. Ann Surg Oncol 2009, 16:20-28.
9. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988, 16:1215.
10. Hu Z., Li C., Chen K., et al. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently normal primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol 2008, 2008:147905.
11. Li G., Sturgis E.M., Wang L.E., et al. Association of a P73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2004, 25:1911-1916.
12. Bojesen S.E., Nordestgaard B.G. The common germline Arg72Pro polymorphism of P53 and increased longevity in humans. Cell Cycle 2008, 7:158-163.
13. Katkoori V.R., Jia X., Shanmugam C., et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009, 15:2406-2416.
14. Lee J.M., Lee Y.C., Yang S.Y., et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus. Int J Cancer 2000, 89:458-464.
15. Hiyama T., Tanaka S., Kitadai Y., et al. p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 2002, 100:304-308.
16. Irarrazabal C.E., Rojas C., Aracena R., et al. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett 2003, 144:69-76.
17. Zhu Z.Z., Wang A.Z., Jia H.R., et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 2007, 37:385-390.
18. Jost C.A., Marin M.C., Kaelin W.G. P73 is a simian (correction of human) p53-related protein that can induce apoptosis. Nature 1997, 389:191-194.
19. Galli P., Cadoni G., Volante M., et al. A case-control study on the combined effects of P53 and P73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer 2009, 9:137.
20. Murphy M.E. Polymorphic variants in the P53 pathway. Cell Death Differ 2006, 13:916-920.
21. Zhu Z.Z., Liu B., Wang A.Z., et al. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B 2008, 9:847-852.
22. Henner W.D., Evans A.J., Hough K.M., et al. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001, 49:263-266.
23. Sjalander A., Birgander R., Hallmans G., et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996, 17:1313-1316.
24. Gemignani F., Moreno V., Landi S., et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004, 23:1954-1956.
25. Ryan B.M., McManus R., Daly J.S., et al. A common P73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer 2001, 85:1499-1503.
26. Li H., Yao L., Ouyang T., et al. Association of P73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 2007, 28:372-377.
27. Sun T., Miao X., Zhang X., et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004, 96:1030-1036.